The BTG2 (B-cell translocation gene 2) antibody is a tool used to detect the BTG2 protein, a member of the BTG/Tob family involved in cell cycle regulation, differentiation, and apoptosis. BTG2. also known as PC3 or TIS21. acts as a tumor suppressor by inhibiting cell proliferation and promoting DNA damage responses. It is transcriptionally regulated by p53 and MYC, linking it to stress responses and oncogenesis. BTG2 expression is frequently downregulated in cancers, including breast, prostate, and colorectal carcinomas, correlating with poor prognosis. Its role extends to neurodegenerative diseases and developmental processes like neurogenesis and stem cell maintenance. Antibodies against BTG2 are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study its expression patterns, subcellular localization, and interactions with partners such as CAF1 (CCR4-NOT complex), which mediates mRNA deadenylation and decay. Research on BTG2 antibodies aids in understanding its dual role in tumor suppression and tissue homeostasis, offering insights into cancer mechanisms, therapeutic resistance, and potential diagnostic biomarkers. Structural studies highlight conserved BTG domains critical for protein-protein interactions, emphasizing its regulatory functions in post-transcriptional gene expression.